Janine Quinter
Medizinische Onkologie und Hämatologie · Dept. I
Randomized Phase II Trial on fitness and comobidity-tailored treatment in elderly patients with newly diagnosed primary CNS Lymphoma (FIORELLA Trial)
Jun 7, 2019
Clinical Studies - Jun 7, 2019 - Dec 31, 2099
Ongoing
Project leader: Hitz Felicitas
Members: Demmer-Steingruber Ruth, Quinter Janine
ENIGMA: Open label, non-randomized, Phase IB study to character-ize safety, tolerability and recommended dose of EDO-S101, a first-in-class alkylating histone deacetylase inhibition (HDACi) fusion molecule, in combination with Nivolumab in patients with refractory, locally advanced or metastatic melanoma
May 2, 2019Neuere Immuntherapien zur Behandlung des fortgeschrit-tenen, metastasierten Melanoms haben zu einer Verbesse-rung des Gesamtüberlebens geführt. Diese Immuntherapien führen zu einer Verstärkung der natürlichen Krebsabwehr durch das Immunsystem. Einig...
Clinical Studies - May 2, 2019 - Dec 31, 2024
Automatically Closed
Project leader: Jörger Markus
Members: Wittwer Yvonne, Quinter Janine
Peace-4
Apr 26, 2019Prostate cancer is the most frequent cancer in Western countries and castrate- resistant prostate cancer (CRPC) is its lethal form. Survival for CRPC patients with metastases now encompasses 30 months, while that for patients without metastases is ab...
Clinical Studies - Apr 26, 2019 - Dec 31, 2099
Ongoing
Project leader: Fischer Stefanie
Members: Kern Julia, Quinter Janine
A Phase 3 Study Comparing Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) vs VELCADE, Lenalidomide, and Dexamethasone (VRd) in Subjects with Previously Untreated Multiple Myeloma who are Eligible for High-dose Therapy
Apr 18, 2019
Clinical Studies - Apr 18, 2019 - Dec 31, 2025
Ongoing
Project leader: Schittenhelm Marcus
Members: Berbic Hong Phuong, Quinter Janine
IBCSG 55-17 “Touch” Phase II open-label, multicenter, randomized trial of neo-adjuvant palbociclib in combination with hormonal therapy and HER2 blockade versus paclitaxel in combination with HER2 blockade for elderly patients with hormone receptor positive/HER2 positive early breast cancer
Dec 4, 2018CDK4/6-Inhibitoren bringen enorme Verbesserungen bei der Behandlung von Patienten mit fortgeschrittenen, HR+ (Hormonrezeptor positiv)/HER2- (human epidermal growth factor receptor 2 negativ) BC (Brustkrebserkrankungen). Palbociclib und andere CDK4/6-...
Clinical Studies - Dec 4, 2018 - Jun 7, 2023
Completed
Project leader: Huober Jens
Members: Demmer-Steingruber Ruth, Quinter Janine
Open-label, non-randomized phase-1 study of liposomal doxorubicin TLD-1 in patients with advanced solid tumors
Oct 26, 2018In dieser Studie wird zum ersten Mal die Sicherheit und Wirksamkeit eines neuen Medikaments (Talidox) bei Menschen untersucht. Bei dem neuen Medikament handelt es sich um einen bekannten Wirkstoff, das Chemotherapeutikum Doxorubicin, welches in einer...
Clinical Studies - Oct 26, 2018 - Dec 22, 2023
Completed
Project leader: Hess Dagmar
Members: Harder Anja, Quinter Janine
Trial SAKK 19/17: First line durvalumab in patients with PD-L1 positve, advanced NSCLC with performance status 2 unsuitable for combination chemotherapy. A multicenter, single-arm phase II trial
Oct 23, 2018Lung cancer is the leading cause of cancer deaths. An estimated 30 to 40% of patients diagnosed with NSCLC have a poor PS defined as a score of 2 or higher on the ECOG scale. PS 2 patients are often underrepresented in clinical trials despite represe...
Clinical Studies - Oct 23, 2018 - Dec 31, 2099
Ongoing
Project leader: Früh Martin
Members: Breuss Kim, Quinter Janine
ODM-201 maintenance therapy in patients with metastatic castration resistant prostate cancer (mCRPC) previously treated with one novel hormonal agent first line and non-progressive disease after second line treatment with a taxane: A multicenter randomized double-blind placebo-controlled phase II trial
Mar 31, 2017
Clinical Studies - Mar 31, 2017 - Jun 6, 2024
Completed
Project leader: Fischer Stefanie
Members: Harder Anja, Quinter Janine
SAKK GRAALL 2014: Multicenter trial for the treatment of Acute Lymphoblastic Leukemia (ALL) in younger adults (18-59 years)
Jun 3, 2016GRAALL-2014 follows the GRAALL-2003 and 2005 trials. The GRAALL-2014 trial is subdivided in three sub-studies: GRAALL-2014/B, GRAALL-2014/T and GRAAPH-2014respectively for patients with B-lineage Ph-negative ALL, T-lineage ALL or Ph+ ALL. France, S...
Clinical Studies - Jun 3, 2016 - Dec 31, 2099
Ongoing
Project leader: Silzle Tobias
Members: Quinter Janine, Demmer-Steingruber Ruth
Investigation of Metformin in patients with castration resistant Prostate Cancer in combination with Enzalutamide vs. Enzalutamide alone (IMPROVE TRIAL)
May 20, 2016The current standard of care for patients with metastatic castration resistant prostate cancer (mCRPC) and dis-ease progression is either treatment with abiraterone acetate and prednisone in asymptomatic or mildly symp-tomatic patients without viscer...
Clinical Studies - May 20, 2016 - Feb 15, 2023
Completed
Project leader: Rothermundt Christian
Members: Donno Monica, Quinter Janine
Anti-PD-L1 antibody MEDI4736 in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC). A multicenter single-arm phase II trial.
Apr 22, 2016
Clinical Studies - Apr 22, 2016 - Aug 28, 2024
Completed
Project leader: Frueh Martin
Members: Breuss Kim, Quinter Janine
A Randomized multicenter phase III trial comparing enzalutamide vs. a combination of Ra223 and enzalutamide in asymptomatic or mildly symptomatic castration resistant prostate cancer patients metastatic to bone. PEACE III
Oct 26, 2015Es handelt sich um eine randomisierte open label Phase III Studie. Die Patienten werden vom Hauptsitz der EORTC zentral im Verhältnis 1:1 für die Therapie mit Enzalutamid oder Enzalutamid (Standartbehandlung) und Ra223 (experi-mentelle Behandlung) r...
Clinical Studies - Oct 26, 2015 - Dec 31, 2099
Ongoing
Project leader: Fischer Stefanie
Members: Demmer-Steingruber Ruth, Quinter Janine
Randomized study with a run-in dose-selection phase to assess the added value of lenalidomide in combination with standard remission-induction chemotherapy and post-remission treatment in patients aged 18-65 years with previously untreated acute myeloid leukemia (AML) or high risk myelodysplasia (MDS) (IPSS-R risk score > 4.5)
May 5, 2015
Clinical Studies - May 5, 2015 - Dec 31, 2099
Ongoing
Project leader: Schittenhelm Marcus
Members: Munz Jeannine, Quinter Janine
Prevention of symptomatic skeletal events with denosumab administered every 4 weeks versus every 12 weeks: A noninferiority phase III trial (SAKK 96/12, REDUSE)
Aug 7, 2014Background: Denosumab, a monoclonal antibody against RANK-Ligand has been shown to be superior to zoledronic acid in delaying time to a first on-study skeletal-related event (SRE) in patients with solid tumors, with no effects on disease progression...
Clinical Studies - Aug 7, 2014 - Dec 31, 2099
Ongoing
Project leader: Fischer Stefanie
Members: Demmer-Steingruber Ruth, Quinter Janine
Randomized study with a run-in feasibility phase to assess the added value of Clofarabine in combination with standard remission-induction chemotherapy in patients aged 18-65 years with previously untreated acute myeloid leukemia (AML) or myelodysplasia (MDS) (RAEB with IPSS ≥ 1.5)
Sep 28, 2013
Clinical Studies - Sep 28, 2013 - Dec 1, 2023
Completed
Project leader: Silzle Tobias
Members: Munz Jeannine, Quinter Janine
Therapieoptimierungsstudie in der Primärtherapie des intermediären Hodgkin Lymphoms: Therapiestratifizierung mittels FDG-PET
Apr 16, 2013
Clinical Studies - Apr 16, 2013 - Aug 30, 2023
Completed
Project leader: Hitz Felicitas
Members: Demmer-Steingruber Ruth, Quinter Janine
Qualitätssicherungsprotokoll zur Toxizitätsreduktion in der Primärtherapie des frühen Morbus Hodgkin (2x ABVD+IF vs 2x AVD+IF)
Dec 30, 2009
Clinical Studies - Dec 30, 2009 - Jun 26, 2024
Completed
Project leader: Hitz Felicitas
Members: Munz Jeannine, Quinter Janine
Qualitätssicherungsprotokoll zur Effektivitätssteigerung in der Primärtherapie des intermediären Morbus Hodgkin (4x ABVD+IF vs 2x BEACOPP eskaliert + 2x ABVD+IF)
Dec 30, 2009
Clinical Studies - Dec 30, 2009 - Jun 26, 2024
Completed
Project leader: Hitz Felicitas
Members: Munz Jeannine, Quinter Janine
A phase III trial evaluating the role of ovarian function suppression and the role of exemestane as adjuvant therapies for premenopausal women with endocrine responsive breast cancer (STP)
Sep 3, 2009
Clinical Studies - Sep 3, 2009 - Dec 31, 2099
Ongoing
Project leader: Huober Jens
Members: Demmer-Steingruber Ruth, Quinter Janine
A Phase III Trial Evaluating the Role of Exemestane Plus GnRH Analogue as Adjuvant Therapy for Premenopausal Women with Endocrine Responsive Breast Cancer
Sep 3, 2009
Clinical Studies - Sep 3, 2009 - Dec 31, 2099
Ongoing
Project leader: Huober Jens
Members: Demmer-Steingruber Ruth, Quinter Janine